Tsukamoto Takashi, Wozniak Krystyna M, Slusher Barbara S
MGI Pharma, Inc., 6611 Tributary Street, Baltimore, MD 21224, USA.
Drug Discov Today. 2007 Sep;12(17-18):767-76. doi: 10.1016/j.drudis.2007.07.010. Epub 2007 Aug 27.
During the past 10 years, substantial progress has been made in the discovery and development of small molecule glutamate carboxypeptidase II (GCP II) inhibitors. These inhibitors have provided the necessary tools to investigate the physiological role of GCP II as well as the potential therapeutic benefits of its inhibition in neurological disorders of glutamatergic dysregulation. This review article details key GCP II inhibitors discovered in the last decade and important findings from preclinical and clinical studies.
在过去十年中，小分子谷氨酸羧肽酶II（GCP II）抑制剂的发现和开发取得了重大进展。这些抑制剂为研究GCP II的生理作用以及抑制其活性在谷氨酸能调节异常的神经系统疾病中的潜在治疗益处提供了必要工具。这篇综述文章详细介绍了过去十年中发现的关键GCP II抑制剂以及临床前和临床研究的重要发现。
